Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
- None.
- None.
Insights
The exploration of Telomir-1's effects on canine osteoarthritis could signal a pivotal shift in the management of this common degenerative condition. Current therapies predominantly focus on symptom management; however, Telomir-1's approach to potentially modify the disease process by targeting telomere lengthening is innovative. It's important to note that the success in canines may not directly translate to human applications due to physiological differences, but it does provide a valuable model for understanding the drug's mechanism and safety profile.
From a veterinary perspective, the potential to offer a treatment that not only alleviates symptoms but also addresses the underlying cause of osteoarthritis would be a significant advancement. The impact on the quality of life for affected canines could be substantial, potentially reducing the reliance on long-term pain management strategies that often come with side effects.
Telomir Pharmaceuticals' collaboration with Argenta represents a strategic move within the biotech sector, focusing on an area of high unmet need—age-related diseases in animals, which can also inform human health. Investors often look for innovative approaches to common diseases and Telomir-1's novel mechanism could attract attention if the study results are positive.
However, it's critical to approach the potential market impact with caution. The path from pre-clinical studies in animals to a successful human drug is fraught with challenges, including regulatory hurdles and the need for extensive safety and efficacy data. While the study's outcome could enhance Telomir's valuation and investor interest, the actual financial impact will depend on the progression to clinical trials in humans and eventual market approval.
The mention of an Investigation New Drug (IND) Application to the FDA is a key regulatory step for Telomir Pharmaceuticals. If the canine study results are favorable, the IND would be the first formal step towards clinical trials in humans. The regulatory landscape for such novel therapies is complex, with the FDA requiring rigorous proof of safety and efficacy.
For stakeholders, the IND submission would be an indicator of Telomir's transition from pre-clinical to clinical development stages. However, the approval process can be lengthy and there's no guarantee of a positive outcome. The company's ability to navigate these regulatory pathways will be critical for its future success and impact on the stock market.
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases
This study is believed to be the first and only known study focused on reversing aging in canines
BALTIMORE, March 26, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.
The study will evaluate the efficacy of Telomir-1 for mitigating the progression of osteoarthritis based on symptomatic, radiographic, gross pathologic and histopathologic evaluations. In addition, Telomir believes that this study could be used as part of its pre-clinicial program for eventually evaluating Telomir-1 in humans.
It is estimated that nearly 18 million canines in the United States are affected by osteoarthritis. Of those, only one third of the afflicted canines have a confirmed diagnosis and are being treated for the disease. Current treatments only address the symptoms of osteoarthritis, using behavioral therapies like weight management and pain medications such as NSAIDs and injectables.
“Osteoarthritis is the most common ailment in canines yet there are currently no treatments that combat the disease. As with human osteoarthritis, medical professionals are limited to treatments that only help manage the symptoms,” stated Chris Chapman, MD, Co-founder, Chairman, Chief Executive Officer and President of Telomir Pharmaceuticals. “Working with Argenta, a leading worldwide animal health research company, this study has the potential to demonstrate both the efficacy of Telomir-1 as well as a benign safety profile. We believe that Telomir-1 will offer an attractive treatment for this indication. Just as important, we believe that the results of this trial could be used to enable our submission of an Investigation New Drug Application to the FDA to study the potential effect of Telomir-1 on osteoarthritis in humans.”
“Based on our initial research, we believe that Telomir-1 can offer an effective disease-modifying therapy that enhances the quality of life and mobility for canines with osteoarthritis,” commented Dr. Michael Roizen, Special Advisor on Age Reversal to Telomir Pharmaceuticals. “As with human indications, we believe that Telomir-1 may have the potential to treat age-related conditions in canines through telomere regeneration as we believe it may enable the production of more stem cells which essentially may allow the body, in effect, to repair itself.”
To be added to the Telomir Pharmaceuticals email distribution list, please email telomir@kcsa.com with TELO in the subject line.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents us with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop and commercialize Telomir-1 (which is proposed to be dosed orally) for hemochromatosis (iron overload) and ultimately post-chemotherapy recovery and a broader range of other age-related inflammatory conditions such as osteoarthritis.
The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of the Company’s management related thereto contains “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Telomir’s technologies potential in reversing age-related decline and TELOMIR-1’s ability to result in an individual’s ability to repair oneself by using TELOMIR-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company’s control) that could cause actual results (including the results of the proposed canine osteoarthritis study referenced herein) to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning Telomir's programs and operations are described in additional detail in its registration statement on Form S-1 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company’s website at https://ir.telomirpharma.com. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
For further information, please contact:
KCSA Strategic Communications
Phil Carlson
telomir@kcsa.com
Telomir Pharmaceuticals
info@Telomirpharma.com
(813) 864-2558
FAQ
What is the focus of the study involving Telomir Pharmaceuticals and Argenta?
How long will the study on Telomir-1's efficacy last?
What potential impact does Telomir-1 aim to have on osteoarthritis treatment?
Who is involved in the study with Telomir Pharmaceuticals?
What is the estimated number of canines affected by osteoarthritis in the United States?
